-
ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round
•
China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB 100 million (USD 13.89 million) in a Series B financing round. The round was led by a fund jointly initiated by AstraZeneca and CICC Capital, with participation from existing investor Ascendum Capital. The proceeds will…
-
Ascentage Pharma Receives Drug Production License for Suzhou Plant
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following the successful on-site inspection of its global industrial plant. This marks the first such license granted in Suzhou this year, highlighting the company’s significant progress in expanding its manufacturing capabilities. Plant Profile and CapabilitiesThe GMP-…
-
Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea
•
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan Food and Drug Administration and Orphan Drug Designation (ODD) from the Ministry of Food and Drug Safety in South Korea for its lead product Nefecon (targeted-release budesonide). These designations are for the treatment of primary…
-
Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo
•
The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine hub. This initiative aims to integrate the strengths of three key cities in China’s biomedicine industry, leveraging their unique advantages to drive further growth and innovation. Cities’ Profiles Hub’s PerformanceThe Taizhou-Wuxi-Lianyungang hub can boast over…
-
Huadong Medicine Partners with Dongyang Med for Equity Collaboration
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang Dongyang Medical Materials Co., Ltd. The partnership aims to strengthen the supply of drugs and medical devices in the city of Dongyang. Financial details of the transaction were not disclosed. Transaction DetailsFollowing the deal, Dongyang…
-
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its HR20031 in patients with type 2 diabetes. This marks a significant step forward in the development of a novel treatment option for patients with poorly controlled…
-
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary, Shanghai Henlius Biotech (HKG: 2696), has completed a clinical trial filing for HLX301 in Australia. Henlius will conduct a Phase I clinical study in the country for the bispecific antibody (BsAb) targeting programmed-death-ligand 1 (PD-L1)…
-
Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study
•
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global first-in-man (FIM) clinical study of its MonarQ transcatheter tricuspid valve replacement (TTVR) system. This marks a significant milestone in the development of innovative treatments for tricuspid regurgitation. MonarQ TTVR System ProfileThe MonarQ TTVR system is…
